openPR Logo
Press release

Lawsuit filed for Investors in formerly Aetna who received shares of CVS Health Corporation (NYSE: CVS) in the Takeover

09-26-2019 06:52 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in CVS Health Corporation (NYSE: CVS) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in CVS Health Corporation (NYSE: CVS) shares over alleged securities laws violations.

An investor, who purchased shares of CVS Health Corporation (NYSE: CVS), filed a lawsuit over alleged violations of Federal Securities Laws by CVS Health Corporation in connection with CVS’s acquisition of Aetna on November 28, 2018.

Investors who acquired shares of CVS Health Corporation (NYSE: CVS) in connection with CVS’s acquisition of Aetna on November 28, 2018, you have certain options and for certain investors are short and strict deadlines running. Deadline: October 14, 2019. NYSE: CVS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On May 20, 2015, CVS Pharmacy, Inc., a wholly owned subsidiary of CVS Health Corporation, entered into a merger agreement to acquire Omnicare, Inc., a provider of pharmaceuticals and related pharmacy services to long-term care (“LTC”) facilities and a provider of specialty pharmacy and commercialization services for the bio-pharmaceutical industry.

On December 3, 2017, CVS Health and Aetna announced the execution of a merger agreement under which CVS Health will acquire all outstanding shares of Aetna for a combination of cash and stock. Under the terms of the merger agreement, Aetna shareholders will receive $145.00 per share in cash and 0.8378 CVS Health shares for each Aetna share. Based on a closing price of $75.12 per NYSE:CVS share on December 1, 2017 investors in NYSE:AET shares will receive a value of approximately $207.94 per NYSE:AET shares.

In connection with the acquisition of Aetna, CVS Health Corporation filed with the SEC a Registration Statement, which was declared effective on February 9, 2018, and a joint proxy statement/prospectus on Form 424B3 (collectively the “Offering Documents”).

In March 2018, CVS Health Corporation raised $40 billion in debt securities to help fund the cash component to be paid to Aetna shareholders. The balance of consideration due to Aetna shareholders would be paid in shares of CVS stock.
On March 13, 2018, Aetna shareholders approved the Acquisition (including the provisions whereby Aetna shareholders would exchange their Aetna shares for CVS shares).
Then, in August 2018, CVS Health Corporation disclosed it was “clearly disappointed with [the] performance in the Omnicare business” and that, since the third quarter of 2017, CVS Health Corporation had been “closely monitoring the performance of the [Omnicare] business for potential indicators of impairment.”

On November 28, 2018, the defendants announced that the Acquisition was formally closed, with Aetna shareholders receiving CVS Health Corporation stock valued at $80 per share.

In late February 2019, CVS Health Corporation announced a second multi-billion-dollar impairment charge to its Omnicare-related goodwill, this time a $2.2 billion impairment to be recognized in the fourth quarter of 2018. CVS Health Corporation cited “operational challenges” as a basis for this second massive charge.

According to the complaint the plaintiff alleges that Aetna shareholders approved the Acquisition not knowing that CVS’s reporting of its goodwill asset was not GAAP-compliant, that the Omnicare-related goodwill was materially impaired, and that the price of CVS Health Corporation shares was materially inflated.

Furthermore, the plaintiff alleges that the Offering Documents that were filed in connection with CVS’s acquisition of Aetna on November 28, 2018 contained materially false and/or misleading statements about CVS Health Corporation’s compliance with Generally Accepted Accounting Principles (“GAAP”). In particular, the plaintiff claims that CVS Health Corporation falsely represented in the Offering Documents that it had properly accounted for its $6+ billion goodwill asset, as reported in the “LTC unit,” associated with CVS’s 2015 acquisition of LTC pharmacies of Omnicare.

Those who purchased shares of CVS Health Corporation (NYSE: CVS) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in formerly Aetna who received shares of CVS Health Corporation (NYSE: CVS) in the Takeover here

News-ID: 1838904 • Views: 875

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Merit Medical Systems, Inc. (NYSE: MMSI …
An investor, who purchased shares of Merit Medical Systems, Inc. (NYSE: MMSI), filed a lawsuit over alleged Securities Laws violations by Merit Medical Systems, Inc. Investors who purchased shares of Merit Medical Systems, Inc. (NYSE: MMSI) have certain options and for certain investors are short and strict deadlines running. Deadline: February 3, 2020. NYSE: MMSI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. South Jordan,
Investigation announced for Investors in TD Ameritrade Holding Corporation (NASD …
An investigation on behalf of investors, who currently hold shares of TD Ameritrade Holding Corporation (NASDAQ: AMTD), was announced concerning whether the takeover of TD Ameritrade Holding Corporation is unfair to NASDAQ: AMTD stockholders. Investors who purchased shares of TD Ameritrade Holding Corporation (NASDAQ: AMTD) and currently hold any of those NASDAQ: AMTD shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The
Investigation announced for Long-Term Investors in Carbonite Inc (NASDAQ: CARB)
An investigation on behalf of current long-term investors in shares of Carbonite Inc (NASDAQ: CARB) concerning potential breaches of fiduciary duties by certain directors and officers of Carbonite Inc was announced. Investors who are current long term investors in Carbonite Inc (NASDAQ: CARB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on Dec. 23rd coming up in Lawsuit that was filed for Investors in iRobo …
A deadline is coming up on December 23, 2019 in the lawsuit filed for certain investors of iRobot Corporation (NASDAQ: IRBT) over alleged securities laws violations by iRobot Corporation. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and there are strict and short deadlines running. Deadline: December 23, 2019. NASDAQ: IRBT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the

All 5 Releases


More Releases for CVS

Global Pharmacy Benefit Management (PBM) Sales Market Report 2018 : CVS Health ( …
Researchmoz added Most up-to-date research on "Global Pharmacy Benefit Management (PBM) Sales Market Report 2018" to its huge collection of research reports. This report studies the global Pharmacy Benefit Management (PBM) market status and forecast, categorizes the global Pharmacy Benefit Management (PBM) market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and
Global Pharmacy Benefit Management (PBM) Market Report 2025: CVS Health (CVS),Ex …
Qyresearchreports include new market research report "Global Pharmacy Benefit Management (PBM) Market Research Report 2018" to its huge collection of research reports. The growth progression of the global Pharmacy Benefit Management (PBM) market is molded by an assorted scope of provincial and global factors and trends, the definite record of which shapes the center of the report. The examination introduces inside and out bits of knowledge into different improvements, recognizes wide
Pharmacy Benefit Management (PBM) Market Future Scope Including Top Players CVS …
HTF MI recently introduced Global Pharmacy Benefit Management (PBM) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are CVS Health (CVS), Express Scripts, OptumRx (UnitedHealth), Humana Pharmacy
GLOBAL PHARMACY RETAILING MARKET- DIPLOMAT, CVS, ALBERTSONS, LOBLAW, GUODA DRUGS …
Global Market Study Evaluate on Pharmacy Retailing Industry by Type, Manufacturers, Application, Type, and Regions, Forecast up to 2022 The scope of the global Pharmacy Retailing market report is: This report offers a comprehensive evaluation of the Pharmacy Retailing market. It does so by in-depth qualitative insights, historical Pharmacy Retailing market data, and verifiable projections about global Pharmacy Retailing market size. The projections featured in the Pharmacy Retailing market report have been
Global Reach Stacker Market- CVS Ferrari, KONECRANES, Kalmar, Hyster, Terex,
Global Industry Study Evaluate on Reach Stacker Market by Type Manufacturers Regions and Application Forecast up to 2022 The scope of the Reach Stacker Report: This report primarily focuses on Reach Stacker in the global market. This report generally covers Reach Stacker market in North America Reach Stacker market in Asia-Pacific Reach Stacker market in Europe Reach Stacker market in Latin America Middle as well as Africa. This report partitions the Reach
CVS Group Founder & CEO Hiroto Shizuka To Retire In 2015
In a surprise announcement made this morning at CVS Group’s headquarters in Tokyo, company founder and CEO Hiroto Shizuka announced he will retire in January 2015 due to health concerns. Since CVS Group was founded in 2005 by Hiroto Shizuka, the company has grown immensely, and become a leader in the field of small-cap equity research. Founder Mr Hiroto Shizuka commented following his retirement announcement saying “I dedicated my whole